NET ASSET VALUE – 31 March 2026
2 april, 08:00
On the 31 March 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,670 million and NAV per share was SEK 41.90. Return on NAV per share in the month was -1.09%.
Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
Product Development | ||||
Lipum | 100% | 348 | 3.97 | 9.5% |
Prokarium | 50% | 281 | 3.21 | 7.7% |
Xspray Pharma | 18% | 225 | 2.57 | 6.1% |
Empros Pharma | 79% | 204 | 2.33 | 5.6% |
KAHR Medical | 34% | 204 | 2.33 | 5.6% |
Atrogi | 44% | 197 | 2.25 | 5.4% |
Bonsai Biotherapeutics | 100% | 158 | 1.80 | 4.3% |
Xintela | 60% | 128 | 1.46 | 3.5% |
Microbiotica | 10% | 126 | 1.44 | 3.4% |
AnaCardio | 13% | 79 | 0.91 | 2.2% |
Geneos Therapeutics | 12% | 68 | 0.78 | 1.9% |
Mendus | 23% | 62 | 0.70 | 1.7% |
EpiEndo Pharmaceuticals | 9% | 54 | 0.62 | 1.5% |
Vitara Biomedical | 11% | 54 | 0.61 | 1.5% |
Buzzard Pharmaceuticals | 14% | 32 | 0.36 | 0.9% |
Egetis Therapeutics | 1% | 27 | 0.31 | 0.7% |
Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
Strike Pharma | 18% | 11 | 0.12 | 0.3% |
Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
Total | 2,269 | 25.90 | 61.8% | |
Commercial Growth | ||||
Symcel | 30% | 204 | 2.33 | 5.6% |
NorthX Biologics | 61% | 202 | 2.30 | 5.5% |
Chromafora | 28% | 137 | 1.57 | 3.7% |
Nanologica | 50% | 59 | 0.68 | 1.6% |
Frontier Biosolutions | 2% | 26 | 0.30 | 0.7% |
Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
Total | 630 | 7.19 | 17.2% | |
Assets related to Portfolio companies | 183 | 2.08 | 5.0% | |
Other assets and liabilities | 589 | 6.73 | 16.1% | |
Net Asset Value | 3,670 | 41.90 | 100.0% | |
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE – 31 March 2026
Ämnen i artikeln
NET ASSET VALUE – 31 March 2026
2 april, 08:00
On the 31 March 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,670 million and NAV per share was SEK 41.90. Return on NAV per share in the month was -1.09%.
Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
Product Development | ||||
Lipum | 100% | 348 | 3.97 | 9.5% |
Prokarium | 50% | 281 | 3.21 | 7.7% |
Xspray Pharma | 18% | 225 | 2.57 | 6.1% |
Empros Pharma | 79% | 204 | 2.33 | 5.6% |
KAHR Medical | 34% | 204 | 2.33 | 5.6% |
Atrogi | 44% | 197 | 2.25 | 5.4% |
Bonsai Biotherapeutics | 100% | 158 | 1.80 | 4.3% |
Xintela | 60% | 128 | 1.46 | 3.5% |
Microbiotica | 10% | 126 | 1.44 | 3.4% |
AnaCardio | 13% | 79 | 0.91 | 2.2% |
Geneos Therapeutics | 12% | 68 | 0.78 | 1.9% |
Mendus | 23% | 62 | 0.70 | 1.7% |
EpiEndo Pharmaceuticals | 9% | 54 | 0.62 | 1.5% |
Vitara Biomedical | 11% | 54 | 0.61 | 1.5% |
Buzzard Pharmaceuticals | 14% | 32 | 0.36 | 0.9% |
Egetis Therapeutics | 1% | 27 | 0.31 | 0.7% |
Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
Strike Pharma | 18% | 11 | 0.12 | 0.3% |
Alder Therapeutics | 30% | 0 | 0.00 | 0.0% |
Total | 2,269 | 25.90 | 61.8% | |
Commercial Growth | ||||
Symcel | 30% | 204 | 2.33 | 5.6% |
NorthX Biologics | 61% | 202 | 2.30 | 5.5% |
Chromafora | 28% | 137 | 1.57 | 3.7% |
Nanologica | 50% | 59 | 0.68 | 1.6% |
Frontier Biosolutions | 2% | 26 | 0.30 | 0.7% |
Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
Total | 630 | 7.19 | 17.2% | |
Assets related to Portfolio companies | 183 | 2.08 | 5.0% | |
Other assets and liabilities | 589 | 6.73 | 16.1% | |
Net Asset Value | 3,670 | 41.90 | 100.0% | |
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE – 31 March 2026
Ämnen i artikeln
Banker
Analys
Ericsson
Internationellt
Banker
Analys
Ericsson
Internationellt
Marknadsöversikt
1 DAG %
Senast
1 mån
